CEO and Board of Directors have exercised warrants of series TO 1
Copenhagen, Denmark, 8 December 2021 – The CEO and members of the Board of Directors of Cessatech A/S (“Cessatech” or the “Company”) have exercised all their warrants of series TO 1 that were issued in connection with the Company’s IPO of units that took place in November/December 2020. The exercise period runs until and including 16 December 2021. In total 175,518 warrants of series TO 1 have been exercised by the CEO and members of the Board of Directors. Upon full exercise of the warrants of series TO 1, Cessatech will receive DKK 25.2 million before deduction of transaction related costs.
Warrants of series TO 1
In connection with the Company’s IPO in November/December 2020, Cessatech issued units (shares and free of charge warrants). In total there are 2,520,000 outstanding warrants of series TO 1. The CEO Jes Trygved and members of the Board of Directors, with Chairman Adam Steensberg have exercised their warrants, in total 175,518 warrants, which equals DKK 1,755,180.
Jes Trygved, CEO.....................................39.891 warrants
Board members
Adam Steensberg, Chairman....................27.922 warrants
Charlotte Videbaek (C-ApS)......................42.868 warrants
Ulla Buhl (Buhl Krone Holding ApS)..........19.946 warrants
Martin Olin.................................................39.891 warrants
Peter Birk...................................................5.000 warrants
Flemming S. Jensen..................................n/a*
* not permitted according to employment contract
The warrants of series TO 1 are traded on Spotlight Stock Market until 14 December 2021 but can be exercised until the last day in the exercise period, 16 December 2021. Thereafter the warrants will be cancelled.
For further information regarding the exercise of warrants, please contact:
Sedermera Fondkommission
Phone: +46 40 - 615 14 10
E-mail: info@sedermera.se
www.sedermera.se
Nordic Issuing
Phone: +46 (0)40-632 00 20
E-mail: info@nordic-issuing.se
www.nordic-issuing.se
For more information about Cessatech, please contact:
Jes Trygved, CEO
Phone: +45 9387 2309
E-mail: jes.trygved@cessatech.com
www.cessatech.com
About Cessatech
Cessatech A/S is a Danish pharmaceutical company committed to developing and commercialising evidence-based and innovative medicines for children for the treatment of paediatric acute pain. Its lead asset (CT001) is an analgesic nasal spray for the treatment of acute and planned painful procedures in children. The advantages include needle-free administration, being easy to administer, a fast-acting therapeutic effect and being medically approved for children. CT001 is expected to enter late stage clinical development in 2021.